Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab

Nature Reviews Drug Discovery

Volumn 11, Issue 5, 2012, Pages 401-419

  Lacey, David L ^a   Boyle, William J ^b   Simonet, W Scott ^a   Kostenuik, Paul J ^a   Dougall, William C ^c   Sullivan, John K ^a   Martin, Javier San ^a   Dansey, Roger ^a  

^a AMGEN INC   (United States)

^b VivaMab LLC   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; BONE MASS; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CATARACT; CELLULITIS; COLON CANCER; CYTOLOGY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ERYSIPELAS; FRACTURE; FRACTURE NONUNION; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; LUNG CANCER; MULTIPLE MYELOMA; NON VERTEBRA FRACTURE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOMA; OSTEOLYSIS; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VERTEBRA FRACTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE RESORPTION; DRUG DESIGN; HUMANS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84860364397     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3705     Document Type: Review

References (156)

1. Adams, M. D. et al. Sequence identification of 2,375 human brain genes. Nature 355, 632-634 (1992).
2. Adams, M. D., Kerlavage, A. R., Fields, C. & Venter, J. C. 3,400 new expressed sequence tags identify diversity of transcripts in human brain. Nature Genet. 4, 256-267 (1993).
3. Adams, M. D., Soares, M. B., Kerlavage, A. R., Fields, C. & Venter, J. C. Rapid cDNA sequencing (expressed sequence tags) from a directionally cloned human infant brain cDNA library. Nature Genet. 4, 373-380 (1993).
4. Simonet, W. S., Bucay, N., Lauer, S. J. & Taylor, J. M. A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J. Biol. Chem. 268, 8221-8229 (1993).
5. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
6. Schreiber, M., Rajarathnam, K. & McFadden, G. Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFα, but the dimer is a more potent TNF inhibitor. J. Biol. Chem. 271, 13333-13341 (1996).
7. Smith, C. A., Farrah, T. & Goodwin, R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959-962 (1994).
8. Udagawa, N. et al. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 125, 1805-1813 (1989).
9. Tsuda, E. et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234, 137-142 (1997).
10. Bucay, N. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268 (1998).
11. Martin, T. J. Paracrine regulation of osteoclast formation and activity: milestones in discovery. J. Musculoskelet. Neuronal Interact. 4, 243-253 (2004).
12. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
13. Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998).
14. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
15. Wong, B. R. et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194 (1997).
16. Dougall, W. C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999).
17. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999).
18. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
19. Li, J. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl Acad. Sci. USA 97, 1566-1571 (2000).
20. The American Society for Bone and Mineral Research President's Committee on Nomenclature. Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J. Bone Miner. Res. 15, 2293-2296 (2000).
21. Schlondorff, J., Lum, L. & Blobel, C. P. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor α convertase. J. Biol. Chem. 276, 14665-14674 (2001).
22. Hikita, A. et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand. J. Biol. Chem. 281, 36846-36855 (2006).
23. Suzuki, J. et al. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem. Biophys. Res. Commun. 314, 1021-1027 (2004).
24. Mizuno, A. et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J. Bone Miner. Metab. 20, 337-344 (2002).
25. Eghbali-Fatourechi, G. et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111, 1221-1230 (2003).
26. Lam, J., Nelson, C. A., Ross, F. P., Teitelbaum, S. L. & Fremont, D. H. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 108, 971-979 (2001).
27. Banner, D. W. et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF β complex: implications for TNF receptor activation. Cell 73, 431-445 (1993).
28. Hymowitz, S. G. et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4, 563-571 (1999).
29. Liu, C. et al. Structural and functional insights of RANKL-RANK interaction and signaling. J. Immunol. 184, 6910-6919 (2010).
30. Dempsey, P. W., Doyle, S. E., He, J. Q. & Cheng, G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14, 193-209 (2003).
31. Wu, H. & Arron, J. R. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 25, 1096-1105 (2003).
32. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
33. Feng, X. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene 350, 1-13 (2005).
34. Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024 (1999).
35. Burgess, T. L. et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538 (1999).
36. Lacey, D. L. et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157, 435-448 (2000).
37. Kanazawa, K. & Kudo, A. Self-assembled RANK induces osteoclastogenesis ligand-independently. J. Bone Miner. Res. 20, 2053-2060 (2005).
38. Crockett, J. C. et al. Signal peptide mutations in RANK prevent downstream activation of NF-κB. J. Bone Miner. Res. 26, 1926-1938 (2011).
39. Rodan, G. A. & Martin, T. J. Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif. Tissue Int. 33, 349-351 (1981).
40. Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nature Med. 17, 1231-1234 (2011).
41. Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nature Med. 17, 1235-1241 (2011).
42. Tomoyasu, A. et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem. Biophys. Res. Commun. 245, 382-387 (1998).
43. Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, H. M. & Dunstan, C. R. Osteoprotegerin (OPG) has potent and sustained antiresorptive activity in postmenopausal women. J. Bone Miner. Res. Abstr. 14, S180 (1999).
44. Bekker, P. J. et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348-360 (2001).
45. Whyte, M. P. & Mumm, S. Heritable disorders of the RANKL/OPG/RANK signaling pathway. J. Musculoskelet. Neuronal Interact. 4, 254-267 (2004).
46. Body, J. et al. A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97, 887-892 (2003).
47. Green, L. L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231, 11-23 (1999).
48. Lonberg, N. Human antibodies from transgenic animals. Nature Biotech. 23, 1117-1125 (2005).
49. Kostenuik, P. J. et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J. Bone Miner. Res. 24, 182-195 (2009).
50. Kearns, A. E., Khosla, S. & Kostenuik, P. J. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29, 155-192 (2008).
51. Abdallah, B. M. et al. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif. Tissue Int. 76, 90-97 (2005).
52. Li, X. et al. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 45, 669-676 (2009).
53. Ominsky, M. S. et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J. Bone Miner. Res. 23, 672-682 (2008).
54. Proell, V. et al. Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone 45, 677-681 (2009).
55. Kostenuik, P. J. et al. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49, 151-161 (2011).
56. Ominsky, M. S. et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 49, 162-173 (2011).
57. Samadfam, R., Xia, Q. & Goltzman, D. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 148, 2778-2787 (2007).
58. Samadfam, R., Xia, Q. & Goltzman, D. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J. Bone Miner. Res. 22, 55-63 (2007).
59. Riggs, B. L. et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N. Engl. J. Med. 322, 802-809 (1990).
60. Sogaard, C. H., Mosekilde, L. & Richards, A. Marked decrease in trabecular bone quality after five years of sodium fluoride therapy-assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. Bone 15, 393-399 (1994).
61. Mundy, G. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev. Cancer 2, 584-593 (2001).
62. Good, C. R., O'Keefe, R. J., Puzas, J. E., Schwarz, E. M. & Rosier, R. N. Immunohistochemical study of receptor activator of nuclear factor κ-B ligand (RANK-L) in human osteolytic bone tumors. J. Surg. Oncol. 79, 174-179 (2002).
63. Grimaud, E. et al. Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol. 163, 2021-2031 (2003).
64. Huang, L., Cheng, Y. Y., Chow, L. T., Zheng, M. H. & Kumta, S. M. Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J. Clin. Pathol. 55, 877-878 (2002).
65. Kitazawa, S. & Kitazawa, R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J. Pathol. 198, 228-236 (2002).
66. Ohshiba, T., Miyaura, C., Inada, M. & Ito, A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br. J. Cancer 88, 1318-1326 (2003).
67. Pearse, R. N. et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl Acad. Sci. USA 98, 11581-11586 (2001).
68. Zhu, J. et al. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J. Biol. Chem. 282, 26656-26664 (2007).
69. Brown, J. M. et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57, 611-616 (2001).
70. Giuliani, N. et al. Human myeloma cells stimulate the receptor activator of nuclear factor-κ B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100, 4615-4621 (2002).
71. Zhang, J. et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235-1244 (2001).
72. Canon, J. et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25, 119-129 (2008).
73. Zheng, Y. et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res. 67, 9542-9548 (2007).
74. Quinn, J. E. et al. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis. 8, 253-259 (2005).
75. Whang, P. G., Schwarz, E. M., Gamradt, S. C., Dougall, W. C. & Lieberman, J. R. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J. Orthop. Res. 23, 1475-1483 (2005).
76. Miller, R. E. et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol. Cancer Ther. 7, 2160-2169 (2008).
77. Feeley, B. et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J. Bone Miner. Res. 21, 1571-1580 (2006).
78. Croucher, P. I. et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98, 3534-3540 (2001).
79. Vanderkerken, K. et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63, 287-289 (2003).
80. Yaccoby, S. et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol. 116, 278-290 (2002).
81. Canon, J. et al. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 46, 1613-1619 (2010).
82. Holland, P. M. et al. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol. Ther. 9, 539-550 (2010).
83. Luger, N. M. et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 61, 4038-4047 (2001).
84. Roudier, M. P., Bain, S. D. & Dougall, W. C. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clin. Exp. Metastasis 23, 167-175 (2006).
85. Honore, P. et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med. 6, 521-528 (2000).
86. Capparelli, C. et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res. 60, 783-787 (2000).
87. Oyajobi, B. O. et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61, 2572-2578 (2001).
88. Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50 (2000).
89. Asselin-Labat, M. L. et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465, 798-802 (2010).
90. Beleut, M. et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl Acad. Sci. USA 107, 2989-2994 (2010).
91. Joshi, P. A. et al. Progesterone induces adult mammary stem cell expansion. Nature 465, 803-807 (2010).
92. Gonzalez-Suarez, E. et al. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol. Cell Biol. 27, 1442-1454 (2007).
93. Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103-107 (2010).
94. Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98-102 (2010).
95. Chlebowski, R. T. et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289, 3243-3253 (2003).
96. Tan, W. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548-553 (2011).
97. Armstrong, A. P. et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68, 92-104 (2008).
98. Holstead-Jones, D. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006).
99. Luo, J. L. et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 446, 690-694 (2007).
100. Cross, S. S. et al. Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J. Clin. Pathol. 59, 716-720 (2006).
101. Van Poznak, C. et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours. J. Clin. Pathol. 59, 56-63 (2006).
102. Leibbrandt, A. & Penninger, J. M. RANK/RANKL: regulators of immune responses and bone physiology. Ann. NY Acad. Sci. 1143, 123-150 (2008).
103. Rossi, S. W. et al. RANK signals from CD4+3? inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J. Exp. Med. 204, 1267-1272 (2007).
104. Knoop, K. A. et al. RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J. Immunol. 183, 5738-5747 (2009).
105. Akiyama, T. et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29, 423-437 (2008).
106. Hikosaka, Y. et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29, 438-450 (2008).
107. Bachmann, M. F. et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189, 1025-1031 (1999).
108. Miller, R. E. et al. Receptor activator of NF-B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J. Immunol. 179, 266-274 (2007).
109. Stolina, M. et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J. Immunol. 179, 7497-7505 (2007).
110. Stolina, M., Guo, J., Faggioni, R., Brown, H. & Senaldi, G. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin. Immunol. 109, 347-354 (2003).
111. Ferrari-Lacraz, S. & Ferrari, S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos. Int. 22, 435-446 (2011).
112. Morony, S. et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 117, 411-420 (2008).
113. Helas, S. et al. Inhibition of receptor activator of NF-κB ligand by denosumab attenuates vascular calcium deposition in mice. Am. J. Pathol. 175, 473-478 (2009).
114. Ock, S. et al. Receptor activator of nuclear factor-κB ligand (RANKL) is a novel inducer of myocardial inflammation. Cardiovasc. Res. 1 Feb 2012 (doi:10.1093/cvr/cvs078).
115. Hanada, R. et al. Central control of fever and female body temperature by RANKL/RANK. Nature 462, 505-509 (2009).
116. Duheron, V. et al. Receptor activator of NF-κB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc. Natl Acad. Sci. USA 108, 5342-5347 (2011).
117. Bekker, P. J. et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004).
118. McClung, M. R. et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006).
119. Bouxsein, M. L. & Delmas, P. D. Vertebral fracture assessment using standard bone densitometry equipment predicts incident fractures in women. Nature Clin. Pract. Endocrinol. Metab. 4, 652-653 (2008).
120. Delmas, P. D., Marin, F., Marcus, R., Misurski, D. A. & Mitlak, B. H. Beyond hip: importance of other nonspinal fractures. Am. J. Med. 120, 381-387 (2007).
121. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
122. Kanis, J. A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos. Int. 4, 368-381 (1994).
123. Boonen, S. et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J. Clin. Endocrinol. Metab. 96, 1727-1736 (2011).
124. Brown, J. P. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, Phase 3 trial. J. Bone Miner. Res. 24, 153-161 (2009).
125. Kendler, D. L. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res. 25, 72-81 (2010).
126. Miller, P. D. et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a Phase 2 clinical trial. J. Clin. Endocrinol. Metab. 96, 394-402 (2011).
127. Bone, H. G. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93, 2149-2157 (2008).
128. Ellis, G. K. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26, 4875-4882 (2008).
129. Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009).
130. Coleman, R. E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27, 165-176 (2001).
131. Coleman, R. E. Emerging strategies in bone health management for the adjuvant patient. Semin. Oncol. 34 (Suppl. 4), 11-16 (2007).
132. Roodman, G. D. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664 (2004).
133. Rosen, L. S. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. 7, 377-387 (2001).
134. Rosen, L. S. et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21, 3150-3157 (2003).
135. Novartis Pharmaceuticals Corporation: Zometa US prescribing information. Novartis website [online], http://www.pharma.us.novartis.com/product/pi/pdf/ Zometa.pdf (2010).
136. Cimino, M. A., Rotstein, C., Slaughter, R. L. & Emrich, L. J. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am. J. Med. 83, 1091-1097 (1987).
137. Launay-Vacher, V. et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res. Treat. 124, 745-753 (2010).
138. Oh, W. K. et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 109, 1090-1096 (2007).
139. Ries, F. & Klastersky, J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am. J. Kidney Dis. 8, 368-379 (1986).
140. Barrett-Lee, P. et al. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr. Med. Res. Opin. 23, 1575-1582 (2007).
141. Body, J. J. et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12, 1221-1228 (2006).
142. Lipton, A. et al. Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 25, 4431-4437 (2007).
143. Fizazi, K. et al. Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27, 1564-1571 (2009).
144. Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010).
145. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011).
146. Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125-1132 (2011).
147. Henry, D. H. et al. Delayed skeletal-related events in a randomized Phase III study of denosumab versus zoledronic acid in patients with advanced cancer. J. Clin. Oncol. Abstr. 28, 9133 (2010).
148. Lipton, A. et al. Comparison of denosumab versus zoledronic acid (ZA) for the treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials. Ann. Oncol. Abstr. 21, 1249P (2010).
149. Smith, M. R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a Phase 3, randomised, placebo-controlled trial. Lancet 379, 1239-1246 (2012).
150. Thomas, D. et al. Denosumab in patients with giant-cell tumour of bone: an open-label, Phase 2 study. Lancet Oncol. 11, 275-280 (2010).
151. Blay, J. et al. Denosumab safety and efficacy in giant cell tumor of bone (GCTB): interim results from a Phase 2 study. J. Clin. Oncol. Abstr. 29, 10034 (2011).
152. Papapoulos, S. et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J. Bone Miner. Res. 27, 694-701 (2012).
153. Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled Phase III trials in cancer patients with bone metastases. Ann. Oncol. 10 Oct 2011 (doi:10.1093/annonc/mdr435).
154. Amgen: Xgeva US prescribing information. Amgen website [online], http://pi.amgen.com/united-states/xgeva/xgeva-pi.pdf (2010).
155. Amgen: Prolia US prescribing information. Amgen website [online], http://pi.amgen.com/united-states/prolia/prolia-pi.pdf (2011).
156. Bolon, B. et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum. 46, 3121-3135 (2002).